Keyphrases
Tacrolimus
100%
HLA-matched Donor
100%
Mycophenolate Mofetil
100%
Post-transplantation Cyclophosphamide (PTCy)
100%
Hazard Ratio
44%
Confidence Interval
44%
Graft-versus-host Disease (GvHD)
44%
Relative Abundance
11%
High Risk
11%
Overall Survival
11%
Transplantation
11%
Haploidentical Hematopoietic Stem Cell Transplantation
11%
Progression-free Survival
11%
Multivariate Analysis
11%
Hematopoietic Stem Cell Transplantation
11%
Bacterial Infection
11%
Calcineurin Inhibitors
11%
Low Risk
11%
Non-relapse Mortality
11%
Relapse Risk
11%
Microbiological Analysis
11%
Neutrophil Engraftment
11%
Antitumor Properties
11%
β-glucuronidase
11%
Steroid-refractory
11%
Antimicrobial Properties
11%
Stool Microbiome
11%
Immunology and Microbiology
Cyclophosphamide
100%
Tacrolimus
100%
Mycophenolate Mofetil
100%
Acute Graft Versus Host Disease
33%
Graft-Versus-Host Disease
22%
Microbiome
11%
Engraftment
11%
Haploidentical Hematopoietic Stem Cell Transplantation
11%
Hematopoietic Stem Cell Transplantation
11%
Overall Survival
11%
Immunosuppressive Drug
11%
Neutrophil
11%
Chronic Graft Versus Host Disease
11%
Progression Free Survival
11%
Antimicrobial Activity
11%